Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Uric acid is the final product of purine metabolism in humans. Elevated levels in the blood (hyperuricemia) can lead to gout and kidney stones, while low levels have been linked to neurological disorders. It acts as an antioxidant at lower concentrations but exhibits pro-inflammatory effects at higher concentrations.
Uric acid itself is not directly targeted by drugs. Interacting drugs target the enzyme xanthine oxidase (e.g., allopurinol, febuxostat) to reduce uric acid production or promote its excretion (e.g., probenecid, lesinurad). Pegloticase converts uric acid to allantoin.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Uric Acid (N/A).